| 4.02 0.13 (3.34%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.8 |
1-year : | 5.6 |
| Resists | First : | 4.11 |
Second : | 4.8 |
| Pivot price | 3.79 |
|||
| Supports | First : | 3.49 |
Second : | 3.11 |
| MAs | MA(5) : | 3.92 |
MA(20) : | 3.72 |
| MA(100) : | 3.63 |
MA(250) : | 2.82 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.4  |
D(3) : | 84.1 |
| RSI | RSI(14): 63.3 |
|||
| 52-week | High : | 4.21 | Low : | 1.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SVRA ] has closed below upper band by 1.5%. Bollinger Bands are 8.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.11 - 4.13 | 4.13 - 4.15 |
| Low: | 3.8 - 3.82 | 3.82 - 3.84 |
| Close: | 3.99 - 4.02 | 4.02 - 4.05 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Fri, 01 Dec 2023
Savara Inc. (NASDAQ:SVRA) most popular amongst private equity firms who own 41% of the shares, institutions hold ... - Yahoo Finance
Tue, 21 Nov 2023
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference - Business Wire
Wed, 08 Nov 2023
Savara to Present at the Jefferies London Healthcare Conference - Yahoo Finance
Fri, 06 Oct 2023
Savara Announces New Employment Inducement Grant - Business Wire
Mon, 11 Sep 2023
Savara Inc.'s (NASDAQ:SVRA) Path To Profitability - Yahoo Finance
Tue, 05 Sep 2023
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 135 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 58.8 (%) |
| Shares Short | 3,880 (K) |
| Shares Short P.Month | 3,870 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.9 % |
| Return on Equity (ttm) | -37.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -12.97 |
| PEG Ratio | 0 |
| Price to Book value | 3.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|